CA2603873A1 - Abuse-resistant amphetamine prodrugs - Google Patents
Abuse-resistant amphetamine prodrugs Download PDFInfo
- Publication number
- CA2603873A1 CA2603873A1 CA002603873A CA2603873A CA2603873A1 CA 2603873 A1 CA2603873 A1 CA 2603873A1 CA 002603873 A CA002603873 A CA 002603873A CA 2603873 A CA2603873 A CA 2603873A CA 2603873 A1 CA2603873 A1 CA 2603873A1
- Authority
- CA
- Canada
- Prior art keywords
- amphetamine
- lysine
- pharmaceutical composition
- auc
- bioavailability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Addiction (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66938505P | 2005-04-08 | 2005-04-08 | |
| US66938605P | 2005-04-08 | 2005-04-08 | |
| US60/669,385 | 2005-04-08 | ||
| US60/669,386 | 2005-04-08 | ||
| US68117005P | 2005-05-16 | 2005-05-16 | |
| US60/681,170 | 2005-05-16 | ||
| US75654806P | 2006-01-06 | 2006-01-06 | |
| US60/756,548 | 2006-01-06 | ||
| US75995806P | 2006-01-19 | 2006-01-19 | |
| US60/759,958 | 2006-01-19 | ||
| PCT/US2006/013221 WO2006121552A2 (en) | 2005-04-08 | 2006-04-10 | Abuse-resistant amphetamine prodrugs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2603873A1 true CA2603873A1 (en) | 2006-11-16 |
Family
ID=37397039
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002603873A Abandoned CA2603873A1 (en) | 2005-04-08 | 2006-04-10 | Abuse-resistant amphetamine prodrugs |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1865980A4 (enExample) |
| JP (1) | JP2008535860A (enExample) |
| BR (1) | BRPI0612440A2 (enExample) |
| CA (1) | CA2603873A1 (enExample) |
| MX (1) | MX2007012507A (enExample) |
| WO (1) | WO2006121552A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8318813B2 (en) | 2007-09-13 | 2012-11-27 | Lcs Group, Llc | Method of treating binge eating disorder |
| WO2010042120A1 (en) | 2008-10-09 | 2010-04-15 | Archimica, Inc. | Process for the synthesis of amphetamine derivatives |
| GB201002612D0 (en) * | 2010-02-16 | 2010-03-31 | Jagotec Ag | Improvements in or relating to organic compounds |
| WO2014002039A1 (en) * | 2012-06-27 | 2014-01-03 | Shire Ag | Amphetamine prodrugs |
| US11879019B2 (en) | 2016-12-19 | 2024-01-23 | The Regents Of The University Of California | Dual-enzyme responsive peptides |
| EP3554548A4 (en) | 2016-12-19 | 2020-08-19 | The Regents of The University of California | NON-CRUSHABLE PILL FORMULATIONS |
| DK3459538T3 (da) | 2017-09-20 | 2020-08-03 | Sandoz Ag | Krystallinske salte af et dextroamfetamin-prodrug |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| KR20220008824A (ko) | 2019-04-17 | 2022-01-21 | 컴퍼스 패쓰파인더 리미티드 | 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법 |
| EP4098248A1 (en) * | 2019-12-30 | 2022-12-07 | Labomed Pharmaceutical Company S.A. | Oral solutions comprising lisdexamfetamine salts |
| AU2021382158C1 (en) | 2020-11-18 | 2026-05-07 | Definium Therapeutics US, Inc. | Mdma prodrugs to assist psychotherapy |
| WO2023111325A1 (en) | 2021-12-16 | 2023-06-22 | Labomed Pharmaceutical Company S.A. | Container comprising a lisdexamfetamine containing oral solution |
| WO2024023367A1 (en) | 2022-07-29 | 2024-02-01 | Labomed Pharmaceutical Company S.A. | Lisdexamfetamine containing oral solution |
| EP4768024A1 (en) | 2024-12-24 | 2026-07-01 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | MINI-TABLETS IN CAPSULE FORMULATIONS OF LISDEXAMFOETAMINE DIMESYLATE |
| WO2026142600A1 (en) | 2024-12-24 | 2026-07-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | A capsule formulation of lisdexamfetamine dimesylate |
| WO2026142601A1 (en) | 2024-12-24 | 2026-07-02 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Capsule formulations of lisdexamfetamine dimesylate |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
| US6384020B1 (en) * | 1999-07-14 | 2002-05-07 | Shire Laboratories, Inc. | Rapid immediate release oral dosage form |
| US7297346B2 (en) * | 2001-05-25 | 2007-11-20 | Cephalon Inc. | Pharmaceutical formulations of modafinil |
| US7105486B2 (en) * | 2002-02-22 | 2006-09-12 | New River Pharmaceuticals Inc. | Abuse-resistant amphetamine compounds |
| EA008864B1 (ru) * | 2003-09-30 | 2007-08-31 | Нью Ривер Фармасьютикалз Инк. | Фармацевтические композиции для предотвращения передозировки или неправильного употребления лекарственных средств |
-
2006
- 2006-04-10 EP EP06769808A patent/EP1865980A4/en not_active Withdrawn
- 2006-04-10 BR BRPI0612440-2A patent/BRPI0612440A2/pt not_active Application Discontinuation
- 2006-04-10 JP JP2008505617A patent/JP2008535860A/ja active Pending
- 2006-04-10 MX MX2007012507A patent/MX2007012507A/es unknown
- 2006-04-10 CA CA002603873A patent/CA2603873A1/en not_active Abandoned
- 2006-04-10 WO PCT/US2006/013221 patent/WO2006121552A2/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007012507A (es) | 2008-03-11 |
| BRPI0612440A2 (pt) | 2010-11-23 |
| EP1865980A4 (en) | 2009-11-11 |
| WO2006121552A3 (en) | 2007-07-05 |
| JP2008535860A (ja) | 2008-09-04 |
| EP1865980A2 (en) | 2007-12-19 |
| WO2006121552A9 (en) | 2007-03-08 |
| WO2006121552A2 (en) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7678771B2 (en) | Abuse-resistant amphetamine prodrugs | |
| US7678770B2 (en) | Abuse-resistant amphetamine prodrugs | |
| US20050054561A1 (en) | Abuse-resistant amphetamine compounds | |
| WO2006121552A9 (en) | Abuse-resistant amphetamine prodrugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |
Effective date: 20130314 |